Zydus Cadila gets USFDA nod to market 2 drugs
Drug firm Zydus Cadila today said it has received final approval from the US health regulator to market two drugs used for the treatment of various c25-04-2018
25-04-2018
Announcement under Regulation 30 (LODR)-Press Release / Media Release
Zydus receives final approval from the USFDA for Methylprednisolone Tablets USP and Cinacalcet Hydrochloride Tablets25-04-2018
Company News: Zydus Cadila
Zydus Cadila has received final approval from the US health regulator to market Diclofenac Sodium Topical Solution, used for treating signs and sympto19-04-2018
Announcement under Regulation 30 (LODR)-Press Release / Media Release
Zydus receives final approval from the USFDA for Diclofenac Sodium Topical Solution19-04-2018
Announcement under Regulation 30 (LODR)-Diversification / Disinvestment
The Company has divested its entire shareholding in Bremer Pharma GmbH, Germany (Bremer), a Wholly Owned Subsidiary of the Company and consequently, Bremer ceased to be a subsidiary of the Company.17-04-2018
Shareholding for the Period Ended March 31, 2018
Cadila Healthcare Ltd has submitted to BSE the Shareholding Pattern for the Period Ended March 31, 2018. For more details, kindly Click here06-04-2018
The Company Shall Submit The Audited Financial Results For The Year Ended On March 31, 2018 Within 60 Days From The End Of The Financial Year.
The Company shall submit the audited financial results for the year ended on March 31, 2018 within 60 days from the end of the financial year.06-04-2018
Compliance Certificate For The Half Year Ended On March 31, 2018
Compliance Certificate for the half year ended on March 31, 201806-04-2018
Statement Of Investor Complaints For The Quarter Ended March 2018
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 1340 Name of the Signatory :- Upen ShahDesignation :- Company Secretary and Compliance Officer06-04-2018